ELISE COLEMAN: Open Payments
NPI 1346945904 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$491 in 22 payments from 13 companies in 2025. Trend: 2023 $254 · 2024 $509 · 2025 $491
Food & beverage: $491
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 4 | $100 |
| Merck Sharp & Dohme LLC | 4 | $74 |
| Deciphera Pharmaceuticals Inc. | 2 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Exelixis Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| AstraZeneca Pharmaceuticals LP | 1 | $24 |
| Geron Corporation | 1 | $23 |
| PFIZER INC. | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
Products named: Vyloy, KEYTRUDA, QINLOCK, LIBTAYO, XTANDI, CABOMETYX, ICLUSIG, ENHERTU.
Industry payments across TX — which companies pay providers there.
